Active cycle of breathing techniques plus routine treatment vs routine treatment alone
Length of hospital stay · people with pneumonia
1 finding from 1 review
- no estimate extracted1 study · 32 participantsVery low
Findings
What do systematic reviews say?
2,447 questions · 2,590 findings · 266 reviews
No studies found 699 · 27%GRADE not reported 289 · 11.2%Very low 614 · 23.7%Low 605 · 23.4%Moderate 322 · 12.4%High 61 · 2.4%
Active cycle of breathing techniques plus routine treatment vs routine treatment alone
Duration of fever · people with pneumonia
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Active cycle of breathing techniques plus routine treatment vs routine treatment alone
Duration of total antibiotic therapy ‐ not reported · people with pneumonia
1 finding from 1 review
- no estimate extracted1 study · 32 participantsVery low
Active cycle of breathing techniques plus routine treatment vs routine treatment alone
Duration of ICU stay ‐ not reported · people with pneumonia
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Active cycle of breathing techniques plus routine treatment vs routine treatment alone
Duration of mechanical ventilation ‐ not reported · people with pneumonia
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Active cycle of breathing techniques plus routine treatment vs routine treatment alone
All‐cause mortality · people with pneumonia
1 finding from 1 review
- no estimate extracted1 study · 32 participantsVery low
Active cycle of breathing techniques plus routine treatment vs routine treatment alone
Cure rate · people with pneumonia
It is very uncertain whether active cycle of breathing techniques plus routine treatment changes cure rate compared with routine treatment alone (very low certainty).
1 finding from 1 review
- RR 0.6 [0.29, 1.23]1 study · 32 participantsVery low
Point‐of‐care biomarkers (C‐reactive protein) for infection vs usual care
Number of participants given an antibiotic prescription at index consultation  · people with acute respiratory infections
1 finding from 1 review
- Biomarkers as point‐of‐care tests to guide prescription of antibiotics in people with acute respiratory infections in… 2022 · Cochrane Headline outcomes onlyno estimate extracted12 studies · 10218 participantsModerate
Point‐of‐care biomarkers (C‐reactive protein) for infection vs usual care
Number of participants given an antibiotic prescription within 28 days · people with acute respiratory infections
1 finding from 1 review
- Biomarkers as point‐of‐care tests to guide prescription of antibiotics in people with acute respiratory infections in… 2022 · Cochrane Headline outcomes onlyno estimate extracted7 studies · 5091 participantsHigh
Point‐of‐care biomarkers (C‐reactive protein) for infection vs usual care
Clinical recovery · people with acute respiratory infections
2 findings from 1 review
- Biomarkers as point‐of‐care tests to guide prescription of antibiotics in people with acute respiratory infections in… 2022 · Cochrane Headline outcomes onlyno estimate extracted4 studies · 3104 participantsModerate
- Biomarkers as point‐of‐care tests to guide prescription of antibiotics in people with acute respiratory infections in… 2022 · Cochrane Headline outcomes onlyno estimate extracted5 studies · 2324 participantsModerate
Point‐of‐care biomarkers (C‐reactive protein) for infection vs usual care
Mortality within 28 days · people with acute respiratory infections
1 finding from 1 review
- Biomarkers as point‐of‐care tests to guide prescription of antibiotics in people with acute respiratory infections in… 2022 · Cochrane Headline outcomes onlyno estimate extracted9 studies · 7737 participantsLow
Point‐of‐care biomarkers (C‐reactive protein) for infection vs usual care
Number of participants in need of a hospital admission within 28 days · people with acute respiratory infections
1 finding from 1 review
- Biomarkers as point‐of‐care tests to guide prescription of antibiotics in people with acute respiratory infections in… 2022 · Cochrane Headline outcomes onlyno estimate extracted10 studies · 7514 participantsModerate
Active drug (etanercept or belimumab) with standard therapy vs placebo + standard care
Remission · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in remission (number of patients with remission) compared with standard therapy with placebo (low certainty).
1 finding from 1 review
- Anti‐cytokine targeted therapies for ANCA‐associated vasculitis 2020 · Cochrane Headline outcomes onlyRR 0.97 [0.89, 1.07]Studies not reportedLow
Active drug (etanercept or belimumab) with standard therapy vs placebo + standard care
Durable remission · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in durable remission compared with standard therapy with placebo (low certainty).
1 finding from 1 review
- Anti‐cytokine targeted therapies for ANCA‐associated vasculitis 2020 · Cochrane Headline outcomes onlyRR 0.93 [0.77, 1.11]Studies not reportedLow
Active drug (etanercept or belimumab) with standard therapy vs placebo + standard care
Major relapse · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in major relapse compared with standard therapy with placebo (low certainty).
1 finding from 1 review
- Anti‐cytokine targeted therapies for ANCA‐associated vasculitis 2020 · Cochrane Headline outcomes onlyRR 2.94 [0.12, 70.67]Studies not reportedLow
Active drug (etanercept or belimumab) with standard therapy vs placebo + standard care
Disease flare · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in disease flare compared with standard therapy with placebo (moderate certainty).
1 finding from 1 review
- Anti‐cytokine targeted therapies for ANCA‐associated vasculitis 2020 · Cochrane Headline outcomes onlyRR 0.98 [0.76, 1.27]Studies not reportedModerate
Active drug (etanercept or belimumab) with standard therapy vs placebo + standard care
Any adverse event · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in any adverse event compared with standard therapy with placebo (low certainty).
1 finding from 1 review
- Anti‐cytokine targeted therapies for ANCA‐associated vasculitis 2020 · Cochrane Headline outcomes onlyRR 1.12 [0.97, 1.29]Studies not reportedLow
Active drug (etanercept or belimumab) with standard therapy vs placebo + standard care
Any severe or serious AE (grade 3, 4 or 5) · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in any severe or serious AE (grade 3, 4 or 5) compared with standard therapy with placebo (low certainty).
1 finding from 1 review
- Anti‐cytokine targeted therapies for ANCA‐associated vasculitis 2020 · Cochrane Headline outcomes onlyRR 1 [0.8, 1.27]Studies not reportedLow
Active drug (etanercept or belimumab) with standard therapy vs placebo + standard care
Withdrawals due to adverse events · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy may leads to higher any withdrawals due to AE compared with standard therapy with placebo (low certainty).
1 finding from 1 review
- Anti‐cytokine targeted therapies for ANCA‐associated vasculitis 2020 · Cochrane Headline outcomes onlyRR 2.66 [1.07, 6.59]Studies not reportedLow
Active drug (etanercept or belimumab) with standard therapy vs placebo + standard care
MortalityNumber of participants: 285(2 RCTs) WGET 2005 · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in mortalityNumber of participants: 285(2 RCTs) WGET 2005 compared with standard therapy with placebo (low certainty).
1 finding from 1 review
- Anti‐cytokine targeted therapies for ANCA‐associated vasculitis 2020 · Cochrane Headline outcomes onlyPeto OR 2.45 [0.55, 10.97]Studies not reportedLow